Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 2017 Wedbush PacGrow Healthcare Conference. Debanjan Ray, chief financial officer and head of corporate development will deliver a corporate overview on August 16, 2017, at 2:30 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Christine Quern [email protected] 202-587-2588 Investor Contact: Trout Group Pete Rahmer [email protected] 646-378-2973
